Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications
- PMID: 23673907
- DOI: 10.1161/CIRCEP.113.000392
Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications
Abstract
Background: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a cardiomyopathy characterized by ventricular arrhythmias and an abnormal right ventricle. Implantable cardioverter defibrillator (ICD) therapy may prevent sudden cardiac death in patients with ARVD/C. Currently, an overview of outcomes, appropriate and inappropriate interventions, and complications of ICD therapy in ARVD/C is lacking.
Methods and results: A literature search was performed to identify studies reporting outcome and complications in patients with ARVD/C who underwent ICD implantation. Of 641 articles screened, 24 studies on 18 cohorts were eligible for inclusion. In case of multiple publications on a cohort, the most recent publication was included in the meta-analysis. There were 610 patients (mean age, 40.4 years; 42% women), who had an ICD for primary or secondary prevention of sudden cardiac death. Risk factors for sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricular tachycardia (58%), and ventricular fibrillation (6%). Antiarrhythmic medication consisted mostly of β-blockers (38%), amiodarone (14%), or sotalol (30%). During the 3.8-year follow-up, annualized cardiac mortality rate was 0.9%, annualized noncardiac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%. The annualized appropriate and inappropriate ICD intervention rates were 9.5% and 3.7%, respectively. ICD-related complications consisted of difficult lead placement (18.4%), lead malfunction (9.8%), infection (1.4%), lead displacement (3.3%), and any complication (20.3%).
Conclusions: Cardiac and noncardiac mortality rates after ICD implantation in patients with ARVD/C are low. Appropriate ICD interventions occur at a rate of 9.5%/y. Inappropriate ICD interventions and complications lead to considerable ICD-related morbidity.
Keywords: arrhythmogenic right ventricular dysplasia/cardiomyopathy; complication; implantable cardioverter defibrillator; prognosis; sudden cardiac death.
Similar articles
-
Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.Circulation. 2010 Sep 21;122(12):1144-52. doi: 10.1161/CIRCULATIONAHA.109.913871. Epub 2010 Sep 7. Circulation. 2010. PMID: 20823389
-
Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.J Am Coll Cardiol. 2004 May 19;43(10):1843-52. doi: 10.1016/j.jacc.2004.01.030. J Am Coll Cardiol. 2004. PMID: 15145110
-
Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.J Am Coll Cardiol. 2011 Sep 27;58(14):1485-96. doi: 10.1016/j.jacc.2011.06.043. J Am Coll Cardiol. 2011. PMID: 21939834
-
Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD?Herz. 2005 Mar;30(2):91-101. doi: 10.1007/s00059-005-2677-6. Herz. 2005. PMID: 15875097 Review.
-
Current and state of the art on the electrophysiologic characteristics and catheter ablation of arrhythmogenic right ventricular dysplasia/cardiomyopathy.J Cardiol. 2015 Jun;65(6):441-50. doi: 10.1016/j.jjcc.2014.12.023. Epub 2015 Mar 25. J Cardiol. 2015. PMID: 25818480 Review.
Cited by
-
Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement.Circulation. 2015 Aug 4;132(5):441-53. doi: 10.1161/CIRCULATIONAHA.115.017944. Epub 2015 Jul 27. Circulation. 2015. PMID: 26216213 Free PMC article.
-
Appropriate and Inappropriate Implantable Cardioverter Defibrillators Therapies in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Patients.Cardiol Res. 2018 Aug;9(4):204-214. doi: 10.14740/cr734w. Epub 2018 Aug 10. Cardiol Res. 2018. PMID: 30116448 Free PMC article.
-
My approach to ventricular tachycardia ablation in patient with arrhythmogenic right ventricular cardiomyopathy/dysplasia.HeartRhythm Case Rep. 2020 Feb 14;6(2):51-59. doi: 10.1016/j.hrcr.2019.09.006. eCollection 2020 Feb. HeartRhythm Case Rep. 2020. PMID: 32099789 Free PMC article. No abstract available.
-
Congenital heart disease confounding the diagnosis of arrhythmogenic right ventricular cardiomyopathy.HeartRhythm Case Rep. 2016 Feb 18;2(4):290-295. doi: 10.1016/j.hrcr.2016.01.007. eCollection 2016 Jul. HeartRhythm Case Rep. 2016. PMID: 28491693 Free PMC article. No abstract available.
-
Congenital heart disease combined with Arrhythmogenic Right Ventricular Cardiomyopathy: A CARE compliant case report and literature review.Medicine (Baltimore). 2020 Jun 19;99(25):e20279. doi: 10.1097/MD.0000000000020279. Medicine (Baltimore). 2020. PMID: 32569162 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical